Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan;35(1):255-263.
doi: 10.1016/j.giec.2024.09.002. Epub 2024 Oct 10.

Molecular Imaging: The New Frontier for Endoscopic Diagnosis and Personalization in Inflammatory Bowel Disease

Raja Atreya  1 , Timo Rath  2 , Markus Friedrich Neurath  2
Affiliations
Review

Molecular Imaging: The New Frontier for Endoscopic Diagnosis and Personalization in Inflammatory Bowel Disease

Raja Atreya et al. Gastrointest Endosc Clin N Am. 2025 Jan.

Abstract

Molecular endoscopy in inflammatory bowel disease (IBD) has made the translation from preclinical studies to clinical trials. The so far performed in vivo studies, using fluorescent antibodies, have addressed areas of heightened clinical interest with unmet needs. These include the distribution of targeted therapies within the mucosa, which could elucidate the most fitting dosing for the individual patient, the mode of action of currently used treatments, and subsequently also the prediction of therapeutic response. Altogether, molecular endoscopy might enable us to base individualized therapeutic decisions on preceded in vivo molecular analysis to optimize treatment in IBD.

Keywords: Fluorescence; Fluorescent antibody; IBD; Molecular endoscopy; Molecular imaging; Mucosa; Prediction of response; Target cell.

PubMed Disclaimer

Conflict of interest statement

Disclosure R. Atreya has served as a speaker, or consultant, or received research grants from AbbVie, Abivax, AstraZeneca, Bristol-Myers Squibb, Celltrion Healthcare, Galapagos, Johnson&Johnson, Lilly, MSD, Pfizer, and Takeda Pharma. DFG-SFB/TRR241 Project No. C02 and IBDome, CRU5024 B04 are funded by the German Research Council (DFG). Further supported by the FIBROTARGET project. The FIBROTARGET project has received funding from the European Union’s Horizon Europe Research & Innovation program under grant agreement no. 101080523. Funded by the European Union. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them. T. Rath has received speaker fees from Olympus Medical, PENTAX Medical, Mauna Kea Technologies, Medtronic, Takeda, Galapagos, Falk, Janssen, AbbVie, Repha, Medical Tribune, and Lilly. M F. Neurath has served as advisor or speaker for Pentax, Roche Pharma, Takeda Pharma, Pfizer, MSD, PPM, Janssen, Gilead, Dr Falk Pharma, Boehringer Ingelheim, Amgen, and AbbVie.

Similar articles

See all similar articles

Cited by

MeSH terms

LinkOut - more resources